• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钙网蛋白突变对骨髓增殖性肿瘤中HLA I类分子表达的影响

Effects of Calreticulin Mutations on HLA Class I Expression in Myeloproliferative Neoplasms.

作者信息

Kaur Amanpreet, Desikan Harini, Pagnucco Grace, Kandarpa Malathi, Talpaz Moshe, Raghavan Malini

机构信息

Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI.

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Rogel Cancer Center, Ann Arbor, MI.

出版信息

bioRxiv. 2025 Jun 27:2025.06.24.661416. doi: 10.1101/2025.06.24.661416.

DOI:10.1101/2025.06.24.661416
PMID:40667261
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12262468/
Abstract

Calreticulin (CRT) is important for human leukocyte antigen (HLA) class I assembly. Somatic mutations of the CRT gene () in hematopoietic lineage cells cause myeloproliferative neoplasms (MPNs). Typically, MPN patient cells have one copy each of the wild-type and mutant allele. We find that heterozygous knock-in of a MPN mutation into human cell lines maintains or slightly induces surface expression of HLA class I allotypes. However, full deficiency of wild-type CRT variably reduces the surface expression of HLA class I allotypes, and MPN CRT mutants fail to restore expression for all tested allotypes. Consistent with the largely heterozygous nature of mutations in MPN, surface HLA class I expression in platelets and monocytes from MPN patients with mutations generally falls within the normal range, with higher average expression measured in monocytes from patients treated with interferon alpha compared with other treatments. Overall, the studies indicate that loss of HLA class I expression in cells deficient in wild-type CRT (the CRT dependency) is allele-dependent and correlates with known effects of the assembly factor tapasin. Furthermore, heterozygous knock-in of a MPN-linked mutation has no effect on some allotypes and slightly induces HLA class I expression for CRT-dependent allotypes.

摘要

钙网蛋白(CRT)对人类白细胞抗原(HLA)I类组装很重要。造血谱系细胞中CRT基因的体细胞突变会导致骨髓增殖性肿瘤(MPN)。通常,MPN患者细胞具有野生型和突变型等位基因各一个拷贝。我们发现,将MPN突变杂合敲入人类细胞系可维持或轻微诱导HLA I类同种异型的表面表达。然而,野生型CRT的完全缺失会不同程度地降低HLA I类同种异型的表面表达,并且MPN CRT突变体无法恢复所有测试同种异型的表达。与MPN中突变主要为杂合性质一致,具有突变的MPN患者血小板和单核细胞表面HLA I类表达通常在正常范围内,与其他治疗相比,用α干扰素治疗的患者单核细胞中平均表达更高。总体而言,这些研究表明,野生型CRT缺陷细胞中HLA I类表达的丧失(CRT依赖性)是等位基因依赖性的,并且与组装因子塔帕辛的已知作用相关。此外,与MPN相关的突变杂合敲入对某些同种异型没有影响,并且对CRT依赖性同种异型轻微诱导HLA I类表达。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a67/12262468/28d551516194/nihpp-2025.06.24.661416v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a67/12262468/a9ce21793dfc/nihpp-2025.06.24.661416v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a67/12262468/78c2035cc17e/nihpp-2025.06.24.661416v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a67/12262468/c59348d30ba5/nihpp-2025.06.24.661416v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a67/12262468/13730655852e/nihpp-2025.06.24.661416v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a67/12262468/4fb72487d7b5/nihpp-2025.06.24.661416v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a67/12262468/28d551516194/nihpp-2025.06.24.661416v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a67/12262468/a9ce21793dfc/nihpp-2025.06.24.661416v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a67/12262468/78c2035cc17e/nihpp-2025.06.24.661416v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a67/12262468/c59348d30ba5/nihpp-2025.06.24.661416v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a67/12262468/13730655852e/nihpp-2025.06.24.661416v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a67/12262468/4fb72487d7b5/nihpp-2025.06.24.661416v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a67/12262468/28d551516194/nihpp-2025.06.24.661416v1-f0006.jpg

相似文献

1
Effects of Calreticulin Mutations on HLA Class I Expression in Myeloproliferative Neoplasms.钙网蛋白突变对骨髓增殖性肿瘤中HLA I类分子表达的影响
bioRxiv. 2025 Jun 27:2025.06.24.661416. doi: 10.1101/2025.06.24.661416.
2
Effects of calreticulin deficiency and myeloproliferative neoplasm (MPN)-linked mutation on cellular calcium signaling.钙网蛋白缺乏和骨髓增殖性肿瘤(MPN)相关突变对细胞钙信号传导的影响。
bioRxiv. 2025 Jun 27:2025.06.25.661618. doi: 10.1101/2025.06.25.661618.
3
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.成人全身麻醉后预防术后恶心呕吐的药物:网状Meta分析
Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.
4
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.用于治疗囊性纤维化的阿他芦醇及类似化合物(针对I类提前终止密码子突变的特定疗法)。
Cochrane Database Syst Rev. 2017 Jan 19;1(1):CD012040. doi: 10.1002/14651858.CD012040.pub2.
5
Treatment for women with postpartum iron deficiency anaemia.产后缺铁性贫血女性的治疗。
Cochrane Database Syst Rev. 2024 Dec 13;12(12):CD010861. doi: 10.1002/14651858.CD010861.pub3.
6
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
7
Prediction of KIR3DL1/Human Leukocyte Antigen binding.KIR3DL1/人类白细胞抗原结合的预测
bioRxiv. 2024 May 5:2024.05.03.592082. doi: 10.1101/2024.05.03.592082.
8
Molecular Profile of BCR-ABL1 Negative Myeloproliferative Neoplasm in a Moroccan Population.摩洛哥人群中 BCR-ABL1 阴性骨髓增殖性肿瘤的分子特征。
Asian Pac J Cancer Prev. 2024 Nov 1;25(11):4013-4025. doi: 10.31557/APJCP.2024.25.11.4013.
9
Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.依伐卡托(Ataluren)及类似化合物(针对 I 类提前终止密码子突变的特异性治疗药物)治疗囊性纤维化。
Cochrane Database Syst Rev. 2023 Mar 3;3(3):CD012040. doi: 10.1002/14651858.CD012040.pub3.
10
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.

本文引用的文献

1
Lysosomal degradation targets mutant calreticulin and the thrombopoietin receptor in myeloproliferative neoplasms.溶酶体降解靶向突变钙网织蛋白和骨髓增殖性肿瘤中的血小板生成素受体。
Blood Adv. 2024 Jul 9;8(13):3372-3387. doi: 10.1182/bloodadvances.2023011432.
2
Effects of calreticulin mutations on cell transformation and immunity.钙网织蛋白突变对细胞转化和免疫的影响。
J Cell Mol Med. 2023 Apr;27(8):1032-1044. doi: 10.1111/jcmm.17713. Epub 2023 Mar 13.
3
Human gene-engineered calreticulin mutant stem cells recapitulate MPN hallmarks and identify targetable vulnerabilities.
人类基因工程改造的钙网织蛋白突变干细胞重现 MPN 特征,并确定可靶向的脆弱性。
Leukemia. 2023 Apr;37(4):843-853. doi: 10.1038/s41375-023-01848-6. Epub 2023 Feb 22.
4
Calreticulin mutations affect its chaperone function and perturb the glycoproteome.钙网蛋白突变影响其伴侣功能并扰乱糖蛋白组。
Cell Rep. 2022 Nov 22;41(8):111689. doi: 10.1016/j.celrep.2022.111689.
5
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.分泌型突变钙网织蛋白作为骨髓增殖性肿瘤中的流氓细胞因子。
Blood. 2023 Feb 23;141(8):917-929. doi: 10.1182/blood.2022016846.
6
The IPD-IMGT/HLA Database.免疫球蛋白和 T 细胞受体基因数据库(IMGT)/人类白细胞抗原数据库(HLA)。
Nucleic Acids Res. 2023 Jan 6;51(D1):D1053-D1060. doi: 10.1093/nar/gkac1011.
7
Molecular basis of MHC I quality control in the peptide loading complex.MHC I 肽加载复合物中质量控制的分子基础。
Nat Commun. 2022 Aug 10;13(1):4701. doi: 10.1038/s41467-022-32384-z.
8
Mechanism of mutant calreticulin-mediated activation of the thrombopoietin receptor in cancers.突变钙网织蛋白介导的癌症中血小板生成素受体激活的机制。
J Cell Biol. 2021 Jul 5;220(7). doi: 10.1083/jcb.202009179.
9
HLA tapasin independence: broader peptide repertoire and HIV control.HLA 肽结合蛋白独立性:更广泛的肽库与 HIV 控制。
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28232-28238. doi: 10.1073/pnas.2013554117. Epub 2020 Oct 23.
10
Variations in MHC class I antigen presentation and immunopeptidome selection pathways.MHC Ⅰ类抗原呈递和免疫肽组选择途径的变化。
F1000Res. 2020 Sep 28;9. doi: 10.12688/f1000research.26935.1. eCollection 2020.